Lipid Mediators in Inflammatory Disorders

This publication has 38 references indexed in Scilit:

• Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.
  Thorax, 1996
• Alteration of n-3 fatty acid composition in lung tissue after short-term infusion of fish oil emulsion attenuates inflammatory vascular reaction
  Critical Care Medicine, 1996
• Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist
  British Journal of Clinical Pharmacology, 1996
• TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;
  Shock, 1996
• Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis
  British Journal of Surgery, 1995
• Clinical activity of leukotriene inhibitors
  International Journal of Immunopharmacology, 1995
• The effect of topical application of the platelet-activating factor-antagonist, Ro 24-0238, in psoriasis vulgaris-a clinical and immunohistochemical study
  Clinical and Experimental Dermatology, 1994
• Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
  The Lancet, 1991
• In vivo inhibition of plasma protein leakage andSalmonella enteritidis—induced mortality in the rat by a specific paf-acether antagonist: BN 52021
  Inflammation Research, 1986
• Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid
  Biochemical and Biophysical Research Communications, 1983